美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Emera Inc.

50.08

-1.7000-3.28%

盤後：51.050.9700+1.94%19:30 EDT

成交量：48.79萬

成交額：2,465.78萬

市值：153.14億

市盈率：22.46

高：51.91

開：51.91

低：50.03

收：51.78

52周最高：55.49

52周最低：45.77

股本：3.06億

流通股本：3.06億

量比：1.75

換手率：0.16%

股息：2.12

股息率：4.24%

每股收益(TTM):2.23

每股收益(LYR):2.47

淨資產收益率：7.56%

總資產收益率：2.91%

市淨率：1.63

市盈率(LYR):20.32

資料載入中...

總覽公司新聞資訊公告

分析師：比特幣已觸及長期下行趨勢線及 21 個月 EMA 均線，站穩當前阻力線方能確認漲勢

奧麥羅斯2026財年第二季度業績：YARTEMLEA推動運營實現收支平衡

TradingKey中文

Emera（EMA）上半年調整後淨利潤增至6.27億加元、淨收入降至6.67億加元

財報前瞻｜Emera Inc.本季度營收預計增15.89%，機構觀點偏謹慎

瑞博生物-B：核心產品VORTOSIRAN針對SPAF的2B期臨床試驗獲EMA批准

歐洲藥品管理局（EMA）：阿斯利康(AZN.US)已撤回其重磅免疫藥物Imfinzi在歐盟的擴展適應症申請。

Rocket Lab股價站穩200日EMA上方：獲NASA合同後是否值得買入？

环球市场播报

恒瑞醫藥(600276.SH)：瑞維魯胺片上市許可申請獲EMA受理

新聞稿：CosmoFarm公布2026年第二季度創紀錄營收超1500萬美元，年化運行率超6000萬美元；新增超80家藥房並擴展AI自動化與設施產能

從跟隨者到定價者：加密市場的角色正在反轉

財報前瞻｜Emera Inc.本季度營收預計增35.49%，盈利質量成看點

羅氏獲歐洲監管機構反饋後，啓動Elevidys基因療法新研究

环球市场播报

港股異動 | 和譽-B(02256)盤中漲近10% FGFR4抑制劑依帕戈替尼獲EMA授予孤兒藥資格

和譽-B(02256)：FGFR4抑制劑依帕戈替尼獲EMA授予孤兒藥資格，用於治療肝細胞癌

交易萬物，永不休市：RWA 永續合約（上）

韓國與新加坡啓動自貿協定升級談判並簽署核電合作備忘錄

百奧泰：Usymro（烏司奴單抗注射液）獲得英國 MHRA 上市批准

美國和伊朗的衝突讓全世界的AI中斷了

持續創新穩拓全球

复星医药官微

復宏漢霖(02696)：帕妥珠單抗生物類似藥HLX11(重組抗HER2結構域II人源化單克隆抗體注射液)獲歐洲藥品管理局(EMA)人用醫藥產品委員會(CHMP)積極審評意見

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/EMA/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":50.08,"timestamp":1787342400000,"preClose":51.78,"halted":0,"volume":487921,"hourTrading":{"tag":"盘后","latestPrice":51.05,"preClose":50.08,"latestTime":"19:30 EDT","volume":175258,"amount":8787992.254964,"timestamp":1787355005298,"change":0.97,"changeRate":0.019369,"amplitude":0.019369},"delay":0,"changeRate":-0.03283120896098885,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"休市中","change":-1.7,"latestTime":"08-21 16:00:00 EDT","open":51.91,"high":51.91,"low":50.025,"amount":24657789.365397997,"amplitude":0.036404,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":51.78,"dividendRate":0.042108,"preHourTrading":{"tag":"盘前","latestPrice":52.07,"preClose":51.78,"latestTime":"09:00 EDT","volume":9,"amount":465.57171,"timestamp":1787317237082,"change":0.29,"changeRate":0.005601,"amplitude":0.030707},"postHourTrading":{"tag":"盘后","latestPrice":51.05,"preClose":50.08,"latestTime":"19:30 EDT","volume":175258,"amount":8787992.254964,"timestamp":1787355005298,"change":0.97,"changeRate":0.019369,"amplitude":0.019369},"volumeRatio":1.7497389305446422,"impliedVol":0.0649,"impliedVolPercentile":0.1633},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":1.7497389305446422,"shares":305783111,"dividePrice":2.121674,"high":51.91,"amplitude":0.036404,"preClose":51.78,"low":50.025,"week52Low":45.77,"pbRate":"1.63","psRate":"2.36","week52High":55.49,"institutionHeld":0,"latestPrice":50.08,"eps":2.229761,"divideRate":0.042366,"volume":487921,"delay":0,"ttmEps":2.229761,"open":51.91,"prevYearClose":49.24,"prevWeekClose":51.51,"prevMonthClose":53.89,"prevQuarterClose":53.02,"fiveDayClose":51.51,"twentyDayClose":54.95,"sixtyDayClose":53.63,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"盤前","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"盤前","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"盤前","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-08-21","current":22.459806,"percent":0.843648,"low":16.637027,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"high":22.07626,"avg":19.793468,"sd":1.503181,"marketCap":15955602988.26},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26}],"updateTime":1787444901756},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661483293","title":"分析師：比特幣已觸及長期下行趨勢線及 21 個月 EMA 均線，站穩當前阻力線方能確認漲勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2661483293","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661483293?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 21:18","pubTimestamp":1787318280,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，加密分析师 Rekt Capital 发布比特币技术图表分析指出，比特币正遭遇宏观下行趋势线阻力，该趋势线与 21 个月 EMA 均线拟合。Rekt Capital 认为，如果比特币在这个拟合的阻力区域受阻，那么可能在 50 个月 EMA 均线处（紫色）获得支撑。总体而言，比特币需要将这两个宏观 EMA 重新转化为新的支撑位，并突破宏观下行趋势线，以确认新一轮牛市。Rekt Capital 系资深加密技术分析师，在 X 平台拥有 56 万粉丝。 ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2284491","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTC.USD.HKCC","BTGD","YBTC","YBIT","STCE","BTF","GBTC","BKCH","BTCL","09042","GDLC","BRRR","HODL","BEGS","SBIT","NGHT","EMA","BTCZ","CRPT","HECO","SMST","BTRN","NCIQ","MSBT","BITX","BTFX","WGMI","03008","03439","ARKY","MSTU","BETH","CBTJ","BTC.USD.CC","BETE","BITW","OOQB","IBIT","BITI","BTCO","BTYB","MBTmain","BITC","BITQ","DAPP","LFGY","BITU","BTCI","MAXI","FBTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659183413","title":"奧麥羅斯2026財年第二季度業績：YARTEMLEA推動運營實現收支平衡","url":"https://stock-news.laohu8.com/highlight/detail?id=2659183413","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659183413?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 04:18","pubTimestamp":1786565932,"startTime":"0","endTime":"0","summary":"Omeros公布2026财年第二季度产品销售净额为2850万美元，高于去年同期的零，主要得益于YARTEMLEA总收入达到3220万美元，较第一季度增长190%。按GAAP计算的净利润为1320万美元，每股基本收益为0.18美元，但其中包含1150万美元的非现金公允价值收益；非GAAP调整后净利润为180万美元。经营活动产生现金410万美元，而在7月份完成6020万美元的可转换票据回购之前，截至6月底的现金及短期投资总额为1.32亿美元。","market":"us","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock5.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/earnings/262100447-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","LU1894683264.USD","BK4007","LU0738911758.USD","LU0203347892.USD","OMER","LU0553294199.USD","LU1003077747.HKD","LU0203345920.USD","BK4588","EMA","LU0868494617.USD","NTAP","LU1894683348.USD","SG9999001440.SGD","LU0661504455.SGD","CEO","LU0949170772.SGD","BK4081","LU2637428348.USD","CMS","BK4087","BK4170","BK4585","LU2500361329.USD","LU0868494708.USD","LU0942090050.USD","BK4208","LU2346227817.USD","LU0545039389.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657648031","title":"Emera（EMA）上半年調整後淨利潤增至6.27億加元、淨收入降至6.67億加元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648031","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657648031?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 19:34","pubTimestamp":1786102483,"startTime":"0","endTime":"0","summary":"金吾财讯 | 北美能源巨头Emera 公布2026年第二季度及上半年财务业绩。2026年二季度，Emera实现调整后净利润2.12亿加元，较上年同期的2.36亿加元有所放缓；净利润为1.05亿加元。2026年上半年，公司调整后净利润达到6.27亿加元，高于2025年上半年的6.15亿加元。期内净收入为6.67亿加元，低于去年同期的7.18亿加元。展望未来，公司预计，2026年调整后每股收益增长将超越其5%-7%的年度目标区间高位，公司重申截至2030年维持5%-7%的复合年均增长承诺。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303564","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148281703","title":"財報前瞻｜Emera Inc.本季度營收預計增15.89%，機構觀點偏謹慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1148281703","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148281703?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 08:42","pubTimestamp":1785458557,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年08月07日盘前发布第二季度财报，市场预期营收增长而利润承压，投资者关注盈利质量与现金流稳定性。一致预期显示，本季度Emera Inc.营收为20.29亿加元，同比增长15.89%；调整后每股收益为0.49加元，同比下降24.17%；EBIT为4.73亿加元，同比增长1.23%，上一季度未披露针对本季度的明确量化指引。上季度公司实现营收28.13亿加元，同比增长5.12%；毛利率50.20%；归属于母公司股东的净利润5.82亿加元，净利率20.69%；调整后每股收益同比增长7.00%，净利润环比增长568.97%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜Emera Inc.本季度营收预计增15.89%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001188","title":"瑞博生物-B：核心產品VORTOSIRAN針對SPAF的2B期臨床試驗獲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001188?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 19:59","pubTimestamp":1785239982,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","IBBJ","BK4081","MDTX","EMA","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653608566","title":"歐洲藥品管理局（EMA）：阿斯利康(AZN.US)已撤回其重磅免疫藥物Imfinzi在歐盟的擴展適應症申請。","url":"https://stock-news.laohu8.com/highlight/detail?id=2653608566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653608566?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 18:07","pubTimestamp":1784887647,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0708994859.HKD","LU2236285917.USD","BK4007","LU2456880835.USD","LU0029864427.USD","LU1829250122.USD","LU0432979614.USD","LU1267930573.SGD","LU2237443382.USD","BK4588","EMA","LU0310800379.SGD","LU2089984988.USD","AZN","LU0109394709.USD","LU2462157665.USD","AZNH","LU0889565916.HKD","LU2237443622.USD","LU2237443465.HKD","LU2468319806.SGD","LU2237443549.SGD","LU2237443895.HKD","LU0128525929.USD","BK4568","LU0289739699.SGD","BK4585","IE00B3T34201.USD","BK4081","LU0320765992.SGD","LU2417539215.USD","LU2237443978.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647037238","title":"Rocket Lab股價站穩200日EMA上方：獲NASA合同後是否值得買入？","url":"https://stock-news.laohu8.com/highlight/detail?id=2647037238","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647037238?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 21:09","pubTimestamp":1782738540,"startTime":"0","endTime":"0","summary":"Rocket Lab股价周一盘前交易时段上涨，此前该公司宣布将收购卫星通信运营商Iridium，交易价值约80亿美元。这一消息叠加近期获得的NASA发射合同，为股价提供了技术面支撑。　　从技术走势来看，Rocket Lab股价在6月25日跌至80.69美元的低点后获得支撑，目前盘前交易于90美元附近，成功站稳200日指数移动平均线上方。　　上周，NASA宣布选择Rocket Lab执行三项Electron火箭发射任务，用于PolSIR和TSIS-2科学任务，预计于2027年初启动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-29/doc-inifauhn5315358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NASA","BK4081","EMA","BK0217","300785"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645409710","title":"恒瑞醫藥(600276.SH)：瑞維魯胺片上市許可申請獲EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2645409710","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645409710?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 16:38","pubTimestamp":1782117505,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司收到了欧洲药品管理局(European Medicines Agency，简称“EMA”)的通知,EMA正式确认并受理公司递交的瑞维鲁胺片的上市许可申请，这是公司首个自主研发的创新药向欧盟递交上市申请。该药品适用于联合雄激素剥夺治疗(ADT)，治疗高瘤负荷的转移性激素敏感性前列腺癌(mHSPC)成年男性患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU0405327148.USD","LU1655091616.SGD","BK0188","LU2543165471.USD","LU1580142542.USD","LU2148510915.USD","LU2097828631.EUR","BK4081","BK0028","LU2289578879.USD","LU2097828557.USD","LU2097828474.EUR","LU0359201885.HKD","LU2097828805.USD","LU2580892789.USD","LU1997245094.SGD","LU2328871848.SGD","EMA","LU0359202008.SGD","LU1023057109.AUD","BK0012","LU1997244956.HKD","01276","LU1146622755.USD","LU2495084118.USD","IPOS","BK1191","LU0405327494.USD","BK0060","LU1064131003.USD","LU2488822045.USD","LU1328615791.USD","LU1781817850.SGD","LU1255011170.USD","LU1997245177.USD","LU2580892862.HKD","BK0196","LU1064130708.USD","LU2097828714.EUR","LU1820825898.SGD","LU1969619763.USD","600276","BK0183","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178964593","title":"新聞稿：CosmoFarm公布2026年第二季度創紀錄營收超1500萬美元，年化運行率超6000萬美元；新增超80家藥房並擴展AI自動化與設施產能","url":"https://stock-news.laohu8.com/highlight/detail?id=1178964593","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178964593?lang=zh_tw&edition=fundamental","pubTime":"2026-06-19 03:35","pubTimestamp":1781811307,"startTime":"0","endTime":"0","summary":"Cosmos Health Inc.今日宣布，其全资子公司CosmoFarm S.A.在2026年第二季度实现了超过1500万美元的创纪录营收，这相当于超过6000万美元的年化运行率。Cosmos Health是一家业务多元化、垂直整合的全球医疗健康集团。在此期间，CosmoFarm在其分销网络中新增了超过80家药房，延续了强劲的客户增长势头，这使其已成为大雅典地区领先的医药批发商之一。为了支持这一加速增长，Cosmos Health正在增加CosmoFarm的资本支出，投资于新的机器人自动化与人工智能系统，以优化采购、库存管理和订单履行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COSM","AGIX","ARTY","AIPO","BK4175","BK4022","BK4232","EMA","BK4081","CHAT","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637806473","title":"從跟隨者到定價者：加密市場的角色正在反轉","url":"https://stock-news.laohu8.com/highlight/detail?id=2637806473","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637806473?lang=zh_tw&edition=fundamental","pubTime":"2026-05-21 12:09","pubTimestamp":1779336566,"startTime":"0","endTime":"0","summary":" 加密平台在 CBRS 上市前成功实现了精准的先期定价，这表明 Crypto 正凭借创新机制，逐步从传统金融的跟随者转变为全球资产的新定价中枢。 ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2266266","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","CBRS","FAZ","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185761853","title":"財報前瞻｜Emera Inc.本季度營收預計增35.49%，盈利質量成看點","url":"https://stock-news.laohu8.com/highlight/detail?id=1185761853","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185761853?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 08:17","pubTimestamp":1777594630,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年05月08日公布最新季度业绩，市场关注营收增速与成本控制的落地情况。根据一致预期，本季度Emera Inc.营收预计为30.09亿加元，同比增长35.49%；调整后每股收益预计为1.15加元，同比增长15.55%；息税前利润预计为7.02亿加元，同比增长7.05%；当前一致预期未提供本季度毛利率及净利润或净利率的具体预测。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Emera Inc.本季度营收预计增35.49%，盈利质量成看点","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627213629","title":"羅氏獲歐洲監管機構反饋後，啓動Elevidys基因療法新研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2627213629","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627213629?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 20:44","pubTimestamp":1776343440,"startTime":"0","endTime":"0","summary":"罗氏公司周四宣布，在收到欧洲药品监管机构的反馈后，将针对其基因疗法 Elevidys 启动一项晚期临床试验。该疗法用于治疗杜氏肌营养不良症，由罗氏与美国 Sarepta Therapeutics 公司合作研发。此前，因两例患者死亡事件与该疗法相关而引发审查，这款药物去年未能获得欧洲药品管理局的批准。Elevidys 目前已在 9 个国家获批用于可自主行走、确诊携带 DMD 基因突变的男孩，其中包括美国。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-16/doc-inhuszrw2800982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624593383","title":"港股異動 | 和譽-B(02256)盤中漲近10% FGFR4抑制劑依帕戈替尼獲EMA授予孤兒藥資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2624593383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624593383?lang=zh_tw&edition=fundamental","pubTime":"2026-04-01 15:57","pubTimestamp":1775030256,"startTime":"0","endTime":"0","summary":"消息面上，和誉宣布，其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格，用于治疗肝细胞癌。目前，依帕戈替尼正在全球多地开展临床研究，此次获EMA授予ODD，将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。除本次获得EMA孤儿药资格外，依帕戈替尼此前还分别获得了美国食品药品监督管理局授予的ODD和快速通道资格认定，以及中国国家药品监督管理局授予的突破性疗法认定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EMA","02256","LU2488822045.USD","IE00B5MMRT66.SGD","BK4081","IE00B543WZ88.USD","BK4585","LU2778985437.USD","LU2476274720.SGD","LU2476274308.USD","BK4588","IE00BPRC5H50.USD","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623581546","title":"和譽-B(02256)：FGFR4抑制劑依帕戈替尼獲EMA授予孤兒藥資格，用於治療肝細胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2623581546","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623581546?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 20:32","pubTimestamp":1774960347,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，公司附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性口服小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格，用于治疗肝细胞癌。目前，依帕戈替尼正在全球多地开展临床研究，此次获EMA授予ODD，将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BPRC5H50.USD","LU2488822045.USD","BK1161","02256","BK4081","LU2778985437.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","EMA","LU2476274308.USD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618601928","title":"交易萬物，永不休市：RWA 永續合約（上）","url":"https://stock-news.laohu8.com/highlight/detail?id=2618601928","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618601928?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 09:24","pubTimestamp":1773105857,"startTime":"0","endTime":"0","summary":" RWA 永续合约正试图用透明的链上“线性杠杆”，颠覆传统金融中成本高昂的末日期权（0DTE）与充满黑箱的差价合约（CFD）市场。 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2250726","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNX.USD.CC","EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616376696","title":"韓國與新加坡啓動自貿協定升級談判並簽署核電合作備忘錄","url":"https://stock-news.laohu8.com/highlight/detail?id=2616376696","media":"核电网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616376696?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 18:22","pubTimestamp":1772533330,"startTime":"0","endTime":"0","summary":"近日，韩国总统李在明对新加坡进行了国事访问，两国就升级韩-兴自由贸易协定及核电合作达成重要共识。韩国产业通商资源部长官与新加坡贸工部代表于3月2日共同签署了《关于启动韩新自贸协定升级谈判的联合宣言》。与此同时，韩国水电与核电公司和新加坡能源市场厅也签署了关于小型模块化反应堆合作的谅解备忘录，这标志着韩国核电企业首次与新加坡政府机构在核电领域建立正式合作关系。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303202141a69d90f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303202141a69d90f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EMA","BK4081","BK4606","NLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616698376","title":"百奧泰：Usymro（烏司奴單抗注射液）獲得英國 MHRA 上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2616698376","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616698376?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 16:33","pubTimestamp":1772526786,"startTime":"0","endTime":"0","summary":"格隆汇3月3日丨百奥泰公布，公司于近日收到了英国药品和健康产品管理局签发的关于Usymro上市批准通知。截至本公告披露日，BAT2206已获得美国FDA、欧洲 EMA 和英国 MHRA 批准上市，美国注册商品名称为STARJEMZA，欧洲注册商品名称为 Usymro；已向中国 NMPA 递交上市许可申请，目前正在评审中。Usymro获得英国 MHRA 上市批准后可在英国进行销售，公司海外销售产品品类得到进一步扩充，将进一步提升公司产品的国际影响力，有望对公司长期经营业绩产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163601a445ce72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163601a445ce72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616836227","title":"美國和伊朗的衝突讓全世界的AI中斷了","url":"https://stock-news.laohu8.com/highlight/detail?id=2616836227","media":"01Founder","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616836227?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 06:51","pubTimestamp":1772491887,"startTime":"0","endTime":"0","summary":"根据路透社和当地媒体随后拼凑出的碎片信息：不明物体击中了数据中心的配套电力设施。为了防止火势蔓延引发更大的次生灾害，自动消防系统接管了现场，电力供应被强制切断。而且受影响的远不止 AI。在过去的战争逻辑中，轰炸的目标是切断能源或交通。这就是现代世界的超距作用。一家估值千亿的 AI 公司，其命脉竟然维系于沙漠中一座机房的安保状况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8rBQys8bxg4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BK4543","GTM","BK4587","BK4023","BK4077","AIYY","APAC","BK4585","UAE","BK4551","BK4528","BK4081","BK4588","EMA"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2616533009","title":"持續創新 穩拓全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2616533009","media":"复星医药官微","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616533009?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 21:49","pubTimestamp":1772459340,"startTime":"0","endTime":"0","summary":"创新抗PD-1单抗汉斯状 迈向更广阔国际市场，复星医药子公司复宏汉霖再拓全球布局03汉利康上市七周年 | 以实证行致远，引领一个更可及的治疗时代七年，足以让一粒创新的种子长成惠及数十万患者的生命之树；七年，也见证了中国首个生物类似药从“破冰者”到“领航者”的征程。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-02/doc-inhprfsh8091981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","02196","CHMP","BK1593","BK4087","BK4081","EMA","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614085473","title":"復宏漢霖(02696)：帕妥珠單抗生物類似藥HLX11(重組抗HER2結構域II人源化單克隆抗體注射液)獲歐洲藥品管理局(EMA)人用醫藥產品委員會(CHMP)積極審評意見","url":"https://stock-news.laohu8.com/highlight/detail?id=2614085473","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614085473?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 22:27","pubTimestamp":1772202451,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，HLX11获EMA人用医药产品委员会积极审评意见，推荐批准HLX11的上市许可申请。倘若获得EC批准，HLX11的集中上市许可将在所有欧盟成员国及欧洲经济区国家冰岛、列支敦士登和挪威生效。HLX11是本公司自主研发的帕妥珠单抗生物类似药。2024年12月，HLX11的上市注册申请获国家药品监督管理局受理。2025年3月，HLX11的上市许可申请获欧洲药品管理局受理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","09939","BK4087","CHMP","HK0000306701.USD","EMA","HK0000165453.HKD","HK0000320223.HKD","HK0000306685.HKD","02696","159938","BK1515","BK4081","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}